In a Delaware case Boehringer Ingelheim accuses the Illinois company of improper conduct in deliberately constructing a patent thicket to protect against generic versions of its blockbuster drug.
With new guidelines set to reshape patent examination, the USPTO head makes the case for revisiting subject matter precedent
The company behind Tik Tok bought out much of a struggling smartphone maker’s patent portfolio in January. USPTO assignments from last week show what assets Beijing-based ByteDance came away with
Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco
The settlement deal ends litigation by the Singapore company’s ZiiLabs unit against Nvidia, and will net shareholders around $17.5 million
Coherus launched Delaware action against Amgen in what is likely to become an increasingly familiar life sciences litigation scenario.
PTAB reforms help fuel a miraculous rise up the latest International IP Index, but a recent Federal Circuit decision on eligibility highlights the serious challenges that remain - especially for life sciences companies
If the Commission and Apple are successful in rewriting the rules for chipmaker's licensing arm beware of unintended consequences that reduce choice and harm consumers, expert analyst states
The Federal Circuit’s precedential judgment in Supernus Pharmaceuticals v Iancu is good news for rights holders – especially those in life sciences
Latest report suggests that result of a strategic review will see the company's product and IP arms separate, but current courtroom tussle with Comcast means the timing is not great
After Microsoft's headline grabbing decision to sign-up to the network last year, LOT CEO “absolutely expects IBM to join” once its Red Hat acquisition is finalised
Swedish company issues statement after an unsourced Chinese media article claims that a probe into its licensing practices is underway
Ford faces new confrontation over alleged infringement of MIT-owned IP, but number of suits against car giant well down from 2012-2014 peak
Brand name pharmaceutical companies are facing a policy-making onslaught; with their IP strategies firmly in the spotlight, many are being forced to speak up for the rights that underpin their products.
Delaware lawsuit is first move to litigate assets since former RPX dealmaker took control of portfolio